Christopher Kirk
2021
In 2021, Christopher Kirk earned a total compensation of $1.7M as President and Chief Scientific Officer at Kezar Life Sciences, a 92% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $203,780 |
|---|---|
| Option Awards | $1,027,078 |
| Salary | $443,000 |
| Other | $12,032 |
| Total | $1,685,890 |
Kirk received $1M in option awards, accounting for 61% of the total pay in 2021.
Kirk also received $203.8K in non-equity incentive plan, $443K in salary and $12K in other compensation.
Rankings
In 2021, Christopher Kirk's compensation ranked 6,746th out of 12,415 executives tracked by ExecPay. In other words, Kirk earned more than 45.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,746 out of 12,415 | 46th |
Division Manufacturing | 2,927 out of 5,508 | 47th |
Major group Chemicals And Allied Products | 1,292 out of 2,378 | 46th |
Industry group Drugs | 1,151 out of 2,099 | 45th |
Industry Pharmaceutical Preparations | 840 out of 1,549 | 46th |
Source: SEC filing on April 26, 2022.
Kirk's colleagues
We found two more compensation records of executives who worked with Christopher Kirk at Kezar Life Sciences in 2021.